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Many prospective epidemiological studies have examined the
relationship between serum cholesterol and ischaemic heart
disease. The discovery of an association of low serum
cholesterol with cancer in these studies was unexpected (Rose
et al., 1974), but many of the studies have confirmed it. An
explanation emerged with the recognition that pre-clinical
cancer lowers serum cholesterol (Rose & Shipley, 1980; Cam-
bien et al.. 1980), probably due to increased low-density-
lipoprotein (LDL) receptor activity in malignant cells (Vitols
et al., 1985). It has been uncertain however whether this
short term effect entirely accounts for the association of low
serum cholesterol with cancer: there is conflicting evidence as
to the presence of an additional long term association not
explained by pre-clinical cancer.
A recent analysis of all the published prospective studies
(Law & Thompson, 1991) showed that there is a long-term
effect. When the data from each published study were ex-
pressed in the same way (as the mean case-control serum
cholesterol difference) and adequate allowance was made for
the pre-clinical effect by omitting the early cancers (those
presenting in the first two years in incidence studies or the
first 5 years in mortality studies), the mean serum cholesterol
was significantly lower in persons who developed cancer than
in those who did not (P<0.001). The long term effect is
small however, equivalent on average to about a 15% in-
creased cancer incidence in the lowest cholesterol quintile
group (the short term association is much greater). There is
also pronounced variation between studies, the effect being
large in some studies but absent in others, confirmed by a
measure of heterogeneity that was also statistically significant
(P = 0.01).
This association of low serum cholesterol with cancer is
not seen in international comparisons. Low cholesterol coun-
tries like Japan and China, Greece and Spain, have lower
rates of heart disease than northern Europe and North
America, but their rates of cancer are no higher. The Seven
Countries Study has confirmed a long-term association of
low cholesterol with both cancer of all sites and lung cancer
within the countries, but has shown no association between
the seven countries (Keys et al., 1985). Variation in serum
cholesterol between countries is determined almost entirely
by dietary differences, whereas variation between individuals
within a country has an important genetic component. The
absence of an international association of low cholesterol
with cancer therefore suggests that low dietary fat does not
predispose to cancer, and indeed both animal studies and
epidemiological evidence indicate that if anything the oppo-
site is the case, high dietary fat being associated with in-
creased cancer risk (Kinlen, 1983; Carroll et al.. 1986; Pren-
tice & Sheppard. 1990).
The long term association of low cholesterol with cancer in
individuals might therefore suggest a genetic linkage between
a gene associated with low cholesterol and another that
predisposes to cancer. It seems more likely however that the
Received 28 October 1991.
explanation lies in lifestyle factors (Law & Thompson, 1991).
The heterogeneity of the association of low cholesterol with
cancer between studies was largely explained by social class.
Studies that had recruited from poorer work-ing class com-
munities showed, on average, a larger long term association,
while studies of professionals showed little or no long term
association. Moreover the association seems limited to
haemopoietic cancers and to lung cancer and other smoking-
related cancers. Data on colon cancer (which is not related to
smoking) showed no long term case-control difference in
serum cholesterol; the association was virtually entirely attri-
butable to the pre-clinical effect. The available data for other
cancers that are not smoking-related also suggested no long-
term association.
The likely explanation for the long term association with
haemopoietic cancers (which was mainly apparent in mor-
tality studies) is that treatment prolongs survival so that the
pre-clinical effect persists for many years. This explanation is
substantiated by the observation that the low serum
cholesterol apparent on diagnosis relates to tumour mass and
LDL receptor activity and rises with remission of disease
following treatment (Vitols et al., 1985; Budd & Ginsberg.
1986).
The lung cancer association is less easily explained. It
appears to be present only in men. International com-
parisions. as with cancer ofall sites, not only fail to show the
association of lung cancer with low serum cholesterol but
show an association with high dietary fat (Wynder et al.,
1987). The sex difference and the social class association
make a genetic linkage unlikely and suggest that an environ-
mental or lifestyle factor is introducing bias. If there were a
bias, it would almost certainly involve tobacco smoking, as
smoking is so powerful a determinant of lung cancer risk.
A smoking-related bias has seemed unlikely because serum
cholesterol is similar in smokers and non-smokers (Craig et
al.. 1989). Smoking has two opposing influences however. It
directly lowers high density lipoprotein (HDL) cholesterol,
but the corresponding reduction in total cholesteral is
countered by a tendency for smokers to increase their LDL
cholesterol by eating more fatty food than do non-smokers,
and LDL cholesterol is higher and HDL cholesterol lower in
smokers than non-smokers (Freedman et al., 1986; Craig et
al.. 1989). The prospective studies showing the inverse
association with cancer measured only total cholesterol. In
more intense smokers (who would be at higher risk of
cancer) the 'pharmacological' effect of smoking lowering
HDL cholesterol might outweigh the dietary association so
that an association of low cholesterol with smoking-related
cancers would arise and so account for the weak association
observed.
There has been unwarranted concern relating to the finding
of excess cancer mortality in treated subjects in two ran-
domised trials of serum cholesterol reduction (Dayton et al.,
1969; Committee of Principal Investigators, 1984). The excess
mortality was not statistically significant in either trial.
follow-up after the termination of the two trials showed no
further excess mortality (Pearce & Dayton, 1971; Committee
of Principal Investigators, 1984), and the other cholesterol
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lowering trials have not shown excess cancer mortality
(indeed one showed significantly excess cancer in controls
(Heady. 1974)). An aspect of the trials that has perhaps been
insuficiently appreciated is their short duration: the average
duration of both trials showing excess cancer mortality in
treated subjects was about 5 years. so the average interval
between cholesterol reduction and cancer death was no more
than 3 years. The cancers present in excess in these two trials
were common carcinomas that would not proceed from
induction to the death of the subject so quickly. and in
general they must have been present in pre-clinical form at
the time of randomisation. The duration of the cholesterol
lowering trials has been too short for them to provide useful
information on a possible association of low serum
cholesterol with cancer.
We can conclude that the association of low serum
cholesterol with cancer in prospective studies cannot entirely
be attributed to the effect of pre-clinical cancer, but that the
long term association is small (much smaller than the direct
association between serum cholesterol and coronary heart
disease) and unlikely to be causal. The evidence does not
support the view that dietary recommendations to lower
saturated fat intake are likely to increase the risk of cancer.
Refees
BUDD. D. & GINSBERG. H. (1986). Hypocholesterolemia and acute
myelogenous leukaemia. Cancer. 58, 1361.
CAMBIEN. F.. DUCIMETIERE. P. & RICHARD. J. (1980). Total serum
cholesterol and cancer mortality in a middle-aged male popula-
tion. Am. J. Epidemiol., 112, 388.
CARROLL. K.K.. BRADEN. L.M.. BELL. J.A. & KALAMEGHAM. R.
(1986). Fat and cancer. Cancer. 58, 1818.
COMMITTEE OF PRINCIPAL INVESTIGATORS. WHO cooperative
trial on primary prevention of ischaemia heart disease with
clofibrate to lower serum cholesterol: final mortality follow-up.
Lancet. i, 600.
CRAIG, W.Y.. PALOMAKI. G.E. & HADDOW. J.E. (1989). Cigarette
smoking and serum lipid and lipoprotein concentrations: an
analysis of published data. Br. Med. J.. 298, 784.
DAYTON. S.. PEARCE. M.L.. HASHIMOTO. S.. DIXON. WJ. &
TOMIYASU. U. (1969). A controled clinical trial of a diet high in
unsaturated fat. Circulation, 39-40 (Suppl It). Ill.
FREEDMAN. D.S.. SRINVASAN. S.R. SHEAR. C.L. & 4 others (1986).
Cigarette smoking initiation and longitudinal changes in serum
lipids and lipoproteins in early adulthood: the Bogalusa Heart
Study. Am. J. Epidemiol.. 124, 207.
HEADY. J.A. (1974). Are PUFA harmful? Br. MWed. J.. i 115.
KEYS. A.. ARAVANIS. C.. BLACKBURN. H. & 8 others (1985). Serum
cholesterol and cancer mortality in the Seven Countries Study.
Am. J. Epidemiol.. 121, 870.
KINLEN. LJ. (1983). Fat and cancer. Br. Med. J.. 286, 1081.
LAW. MR. & THOMPSON. S.G. (1991). Low serum cholesterol and
the risk of cancer an analysis of the published prospective
studies. Cancer Causes and Control. 2, 253.
PEARCE. M.L. & DAYTON. S. (1971). Incidence of cancer in men on a
diet high in polyunsaturated fat. Lancet. i 464.
PRENTICE. R.L. & SHEPPARD. L. (199). Dietary fat and cancer:
consistency of the epidemiological data. and disease prevention
that may follow from a practical reduction in fat consumption.
Cancer Causes & Control. 1, 81.
ROSE. G.. BLACKBURN. H.. KEYS. A. & 5 others (1974). Colon
cancer and blood cholesterol. Lancet. i 181.
ROSE. G. & SHIPLEY. MJ. (1980). Plasma lipids and mortality: a
source of error. Lancet. L 523.
VITOLS. S.. GAHRTON. G.. BJORKHOLM. M. & PETERSON. C. (1985).
Hypocholesterolaemia in malignancy due to elevated low-density-
lipoprotein receptor activity in tumour cells: evidence from
patients with leukaemia. Lancet. H, 1150.
WYNDER. E.L.. HEBERT. J.R. & KABAT. G.C. (1987). Association of
dietary fat and lung cancer. J. NVatl Cancer Inst.. 79, 631.